Recent publications suggest that a new drug, belzutifan, a hypoxia-inducible factor 2-alpha inhibitor shows promise as a therapeutic option for VHL-associated hemangioblastomas, particularly for patients not immediately requiring surgery (reviewed in 32–34). Here, EPAS1 is linked to hemangioblastoma.